A plan to curb dire drug shortages; Europe issues max antitrust fine over Grail deal

Taking stock of the drug industry, from the lab to the medicine chest

July 12, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Brendan Smialowski/AFP/Getty Images STAT+ | How to 'break the logjam'? Economists pitch a plan to curb dire drug shortages The U.S. continues to see shortages of medicines. Marta Wosińka explains how changes to hospital purchasing and drug facilities could help. By Ed Silverman STAT+ | Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal The fine comes after Illumina closed the deal to purchase Grail before getting regulatory clearance. By Andrew Joseph STAT+ | How are insurers handling the Alzheimer's drug Leqembi and related scans? As a condition of coverage, Medicare also rolled out a new patient registry to collect more information from physicians prescribing Leqembi. By Rachel Cohrs Adobe A young girl's custom gene therapy hints at a framework for tailored rare disease treatments Individualized medicines, are often made to treat debilitating genetic conditions that are too rare to garner interest from pharma companies. By Bree Iskandar Opinion: Sickle cell cures are coming. African children can't be left behind Rolling out a new generation of sickle cell cures without a strategy to get them to those with the greatest need is not acceptable. By Jayasree K. Iyer

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser